U.S. Cancer Diagnostics Market Size & Outlook, 2024-2030
U.S. cancer diagnostics market, 2018-2030 (US$M)
Related Markets
U.S. cancer diagnostics market highlights
- The U.S. cancer diagnostics market generated a revenue of USD 41,472.6 million in 2024 and is expected to reach USD 59,527.5 million by 2030.
- The U.S. market is expected to grow at a CAGR of 6.4% from 2025 to 2030.
- In terms of segment, public insurance was the largest revenue generating coverage in 2024.
- Public insurance is the most lucrative coverage segment registering the fastest growth during the forecast period.
Cancer diagnostics market data book summary
| Market revenue in 2024 | USD 41,472.6 million |
| Market revenue in 2030 | USD 59,527.5 million |
| Growth rate | 6.4% (CAGR from 2025 to 2030) |
| Largest segment | Public insurance |
| Fastest growing segment | Public insurance |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Public insurance, Private |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 37.8% of the global cancer diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 59,527.5 million by 2030.
Public insurance was the largest segment with a revenue share of 62.61% in 2024. Horizon Databook has segmented the U.S. cancer diagnostics market based on public insurance, private covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is the largest market for cancer diagnostic tests in North America, owing primarily to the high cancer prevalence in the country and consequent rapid adoption of cancer diagnostic tests. Furthermore, significant technological advancements, an increasing number of FDA approvals for tests, and competition among biotechnology companies are projected to boost market growth over the forecast period.
The emergence of proteome screening tests, as highlighted in a recent study in BMJ Oncology, presents a significant opportunity for the cancer diagnostics market. In January, 2024,Novelna Inc., a pioneering liquid biopsy startup, introduced a screening test named Proximity Extension Assay, which harnesses a sex-specific panel of 10 plasma proteins to potentially detect 18 types of cancers at their earliest stages.
Traditional screening methods, such as colonoscopies, CT scans, and mammograms, have drawbacks, including invasiveness, high costs, and limited accuracy, in detecting early-stage cancers. Furthermore, genomics-based multicancer tests, while promising, often exhibit low sensitivity for early stages and can be financially burdensome.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. cancer diagnostics market size, by coverage, 2018-2030 (US$M)
U.S. Cancer Diagnostics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
